ArQule, Inc.Woburn, MA United States
Company Description
ArQule is pursuing a drug research major in molecular biology, with a focus on cancer cell termination. The biotechnology firm works independently and with other drugmakers to discover new potential drug compounds based on its cancer-inhibiting technology platform. ArQule is developing a portfolio of oncology drugs, with a handful of anti-cancer compounds undergoing clinical trials. It is testing its most advanced candidate, ARQ 197, as a treatment for a variety of tumor types such as non-small cell lung cancer and colorectal cancer through a partnership with
| 19 Presidential Way | Phone: 781-994-0300 | http://www.arqule.com |
| Woburn, MA 01801 | Fax: 781-376-6019 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
ArQule, Inc. Rankings
| S&P 600 | Russell 2000 (June 2011) |
Executives
| 20 executives listed for ArQule, Inc.'s Woburn, MA location. | ||
| Chairman | Patrick Zenner | |
|---|---|---|
| CEO and Director | Paolo Pucci | |
| President, COO, General Counsel, and Secretary | Peter Lawrence | |
Financials
| Company Type | Public - NASDAQ: ARQL Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 103 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on ArQule, Inc. now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
